Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Reuters

Sep 29

Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Veracyte Inc. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571824837"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571824837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571824837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571824837","market":"nz","top_or_hot":-1,"title":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250928:nNDL6gfl3Y:1","article_id":"2571824837","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571824837","pubTimestamp":1759089621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer. Veracyte Inc. has announced new data from the prospective, randomized BALANCE trial , indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology  in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCYT":"Veracyte Inc"},"translate_title":"Veracyte公布里程碑式临床试验结果：PAM50生物标志物预测复发性前列腺癌的激素治疗获益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9},"content_text":"Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer\n    \n\nVeracyte Inc. has announced new data from the prospective, randomized BALANCE trial (NCT03371719), indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer may benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The PAM50 biomarker is currently available for research use on the Decipher GRID platform. Results from the BALANCE trial were presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center, Case Western Reserve University, at the 2025 annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. According to the company, this marks the first prospective validation of a predictive biomarker in a randomized trial for non-metastatic prostate cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928979637) on September 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}